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The IT Future of Medicine (ITFoM, http://www.itfom.eu/) initiative will produce computational models
of individuals to enable the prediction of their future health risks, progression of diseases and selection
and efficacy of treatments while minimising side effects. To be able to move our health care system to
treat patients as individuals rather than as members of larger, divergent groups, the ITFoM initiative,
proposes to integrate molecular, physiological and anatomical data of every person in ‘virtual patient’
models. The establishment of such ‘virtual patient’ models is now possible due to the enormous progress
in analytical techniques, particularly in the ‘-omics’ technology areas and in imaging, as well as in sensor
technologies, but also due to the immense developments in the ICT field.
As one of six Future and Emerging Technologies (FET) Flagship Pilot Projects funded by the European
Commission, ITFoM with more than 150 academic and industrial partners from 34 countries, will foster
the development in functional genomics and computer technologies to generate ‘virtual patient’
models to make them available for clinical application. The increase in the capacity of next generation
sequencing systems will enable the high-throughput analysis of a large number of individuals
generating huge amounts of genome, epigenome and transcriptome data, but making it feasible to
apply deep sequencing in the clinic to characterise not only the patient’s genome, but also individual
samples, for example, from tumours. The genome profile will be integrated with proteome and
metabolome information generated via new powerful chromatography, mass spectrometry and
nuclear magnetic resonance techniques. The individualised model will not only enable the analysis of
the current situation, but will allow the prediction of the response of the patient to different therapy
options or intolerance for certain drugs.Corresponding author: Lehrach, H. (lehrach@molgen.mpg.de)
3 On behalf of ITFoM Consortium.
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erFrom molecular analysis to clinical diagnostic
The global initiative to sequence the human genome with the
publication of the first result was a fundamental breakthrough in
2001 [1,2] and had an enormous influence on the molecular
biology and the entire field of life sciences.
The molecular analysis, in particular the ‘-omics’ technologies,
have been developed subsequently over the last 10 years to grasp
the totality of molecules present in organelles, cells, tissues and
organs in order to obtain an overall view of a biological system.
The development of the ‘-omics’ technologies aims, besides the
optimisation of precision, throughput, multiplexing, speed and
miniaturisation, also at the reduction in the cost per sample, to
allow a routine use in the hospital.
The sequencing technologies take the lead in this development;
very recently market leaders in sequencing technology announced
the launching of new products able to analyse a human genome
within one day at a price of 1.000 USD. Especially in cancer, the
tumour tissue sequencing will be the central basis for treatment
decisions. Since we know now that not just any patient, but also
every tumour is different, sequencing technologies will help to
detect which mutations cause the tumour to grow. Based on this
information, in the future a doctor will be much more accurate in
choosing the right treatment for the individual patient.
With increasing knowledge about the functionality of living
systems, our understanding will continue to grow about protein
modifications and interactions as well as the structure of proteins.
A highly dynamic development can be seen also in the imaging
technologies that give a more precise idea of what is going on in
the body of a patient. The integration of molecular imaging
technologies and sensors will allow us to get an insight view about
molecule behaviour in space and time.
These innovations in analytical technologies in molecular biol-
ogy and their application in medicine induced a paradigm shift
allowing for the application of a new way for medical diagnosis
and treatment. With appropriate diagnostics the clinician or
general practitioner can tailor a medical treatment or a prevention
strategy to an individual patient according to the responding
markers on the gene, protein or metabolite level.
Systems medicine – from clinical diagnosis to improved
treatment
From pharmacogenomics studies it became clear that the common
drug blockbuster strategy (‘one drug fits all’) must be revised
according to the individual responses [3]. It could be shown forinstance that there is a very high number (70–100%) of non-
responders for various cancer drugs indicating that for most cancer
patients a treatment will only generate severe side-effects without
leverage for the disease itself [4].
Thanks to systems biology, a new discipline within the life
sciences, the model-based approaches in human life science are
so promising that they are expected to induce the next paradigm
shift in modern medicine towards an individual-centred health
care. Based on the molecular methods, systems medicine breaks
boundaries deciphering the complex mechanisms of diseases,
accelerates the discovery of new treatments and supports the
evaluation of clinical trials; systems medicine can also be used
to design new molecular diagnostics tools.
Systems biology, with methods and tools for mathematical
analysis integrating and interpreting biological data, develops
and builds mathematical models that allow a simulation and
visualisation of biological processes. Cellular interaction net-
works, which are central to the understanding of biological sys-
tems, can be well represented with the help of mathematical
model approaches [5–7]. The mathematical models developed
in systems biology support the integration and analysis of increas-
ingly large data sets and combine them with existing knowledge to
enable an intelligent interpretation of the data.
Especially in cancer and tumour development, the signalling
pathways play a central role in a mathematical model; ground-
breaking for a basic understanding of the components of cancer
signalling pathways was the publication by Hanahan and Wein-
berg in 2000 [8] with an update in 2011 [9]. The methods of
systems biology developed systematically for more than ten years
require further extensive development to describe adequately the
highly complex processes of a living system (cell, tissue or organ)
and their interrelation. Other challenges are to combine and
integrate the heterogeneous data in the model, and this applies
for the integration of genomic data as well as for data from other
levels of biological information such as proteins and metabolites.
The PyBios model, which has been developed at the Max Planck
Institute for Molecular Genetics, focuses on signal transduction
pathways in cancer [8,9]; this model is using Monte Carlo simula-
tions to study the interaction between the components and to
identify mutations with influence on the system [10].
More information levels will be considered to be integrated in
the future, for instance the metagenome of a human body since
new publications show an influence of intestinal bacteria on the
health status [11,12]. The metagenomic (sequencing) analysis of
the intestinal bacterial population of a human (‘microbiome’) will
provide a powerful analytical method that might be integrated in
the future as a standard procedure in clinical diagnostics.
So far it was still too difficult to capture and integrate most
information about lifestyle and environmental data for the patient
diagnosis. For the preparation of a comprehensive and unique
image of a patient, however, this additional information will be
very important to ensure adequate patient-tailored therapy but
also to develop a robust prevention strategy.
IT Future of Medicine – the future of personalised
medicine
New ground-breaking developments in diagnostic methods
now allow a very precise detection of the health status of awww.elsevier.com/locate/nbt 363
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FIG. 1
The ITFoM computational models will integrate all of the types of all relevant genomic, epigenomic, functional information, imaging, pathology, environment and
metagenomics data, but also individual patient histories as well as the individualised patient models derived from this information accessible to the consenting
patient and his doctor. This comprehensive information package will be integrated with patient clinical records in the same way as blood chemistry, X-rays, MRI





erpatient and his disease. But how can this information for the
individual patient be used efficiently? The European initiative
‘IT Future of Medicine’ is answering this question through the
development of a new, data-rich computational model basedFIG. 2
The map shows the location of partnering institutions in ITFoM. The colour inten
364 www.elsevier.com/locate/nbton integrated molecular, physiological and anatomical data
of every person, the ‘virtual patient’, and the identification
of new avenues for treatment and prevention approaches
(Fig. 1).sity indicates the number of ITFoM partners in each country.








erTo cope with the enormous amount of data that will soon
be generated in modern medicine, targeted Information and
Communication Technology (ICT) developments will be a
prerequisite to empower the ‘virtual patient’ model for the
clinical practice. Solutions for topics like data processing, auto-
mation, storage, compression and in-time availability are
highly relevant to enable the ‘virtual patient’. Efficient pipelines
of samples and resulting data from patient to model have to be
implemented. The transfer of the information from model to
clinician is a critical point for the acceptance of the new
system in the day-to-day practice, for example, visualisation
and human-computer interfaces in particular are demanding
issues that must be optimised for a successful implementation
[13].
All these developments must be accompanied by measures
assuring that legal and ethical issues connected to the ‘virtual
patient’ are adequately addressed and integrated from the begin-
ning. Therefore, the lively interaction with stakeholder groups and
especially patient organisations are highly important for the suc-
cess of the approach.
To develop a ‘virtual patient’ and to apply it for the clinic
routine, further refinement of the analytical technologies is
necessary, but in parallel also the development of solutions for
the computing requirements to process and handle the large
amounts of heterogeneous and complex data. In the ITFoM
consortium, experts from the medical practice, the analytical
technology development and the ICT have joined from all over
the world in order to face this big challenge in a global approach
(Fig. 2).Acknowledgements
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